RE:think Since the 2021 revenues of almost $58 million and aspirations of $400 million in a few years (excluding the 20,000 monthly Biocloud units amounting to billions per year) Ghezzi has grown this exponentially to a company in lower teens before the sale of Ortech. With a relatively small operation there isn't a huge repertoire to pump so we will just have to wait to see what the next thing will be attempted to breathe some life into this for a week or so.